After releasing disappointing phase 3 data early last year and receiving a FDA rejection in August, shares of Portola Pharmaceuticals Portola Pharmaceuticals’ most advanced drugs in development are the factor Xa anticoagulant betrixaban and the factor Xa reversal agent AndexXa. In March, management reported betrixaban phase 3 trial data that left investors questioning the drug’s future.
Category: Portola Pharmaceuticals
article
This week has proven to be a disappointment for bullish investors who were hoping to see the Dow Jones Industrials reach a historic 20,000 milestone. Friday brought slight gains to the overall stock market, but they weren’t enough to push the Dow into uncharted territory, and advances for most major market benchmarks were limited to less than a quarter of one percent.